Log in

Applied Genetic Technologies Stock Forecast, Price & News

+0.07 (+1.30 %)
(As of 10/23/2020 12:00 AM ET)
Today's Range
Now: $5.46
50-Day Range
MA: $5.25
52-Week Range
Now: $5.46
Volume60,956 shs
Average Volume188,537 shs
Market Capitalization$141.20 million
P/E RatioN/A
Dividend YieldN/A
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. The company also has initiated one preclinical program in otology and three preclinical programs in targeting central nervous system disorders, including one in adrenoleukodystrophy. Applied Genetic Technologies Corporation has collaboration agreements with Synpromics Limited and University of Florida; Bionic Sight, LLC; and Otonomy, Inc. The company was founded in 1999 and is headquartered in Alachua, Florida.
Read More
Applied Genetic Technologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.50 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:AGTC



Sales & Book Value

Annual Sales$2.45 million
Book Value$2.76 per share


Net Income$-45,890,000.00


Market Cap$141.20 million
Next Earnings Date11/10/2020 (Estimated)
+0.07 (+1.30 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AGTC News and Ratings via Email

Sign-up to receive the latest news and ratings for AGTC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Applied Genetic Technologies (NASDAQ:AGTC) Frequently Asked Questions

How has Applied Genetic Technologies' stock been impacted by Coronavirus (COVID-19)?

Applied Genetic Technologies' stock was trading at $3.84 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AGTC shares have increased by 42.2% and is now trading at $5.46.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Applied Genetic Technologies?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Applied Genetic Technologies

When is Applied Genetic Technologies' next earnings date?

Applied Genetic Technologies is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Applied Genetic Technologies

How were Applied Genetic Technologies' earnings last quarter?

Applied Genetic Technologies Corp (NASDAQ:AGTC) posted its earnings results on Wednesday, September, 9th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.46) by $0.10.
View Applied Genetic Technologies' earnings history

What price target have analysts set for AGTC?

7 analysts have issued 1 year price objectives for Applied Genetic Technologies' shares. Their forecasts range from $7.50 to $26.00. On average, they anticipate Applied Genetic Technologies' share price to reach $15.93 in the next year. This suggests a possible upside of 191.7% from the stock's current price.
View analysts' price targets for Applied Genetic Technologies

Are investors shorting Applied Genetic Technologies?

Applied Genetic Technologies saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,680,000 shares, an increase of 24.4% from the August 31st total of 1,350,000 shares. Based on an average trading volume of 393,200 shares, the days-to-cover ratio is currently 4.3 days.
View Applied Genetic Technologies' Short Interest

Who are some of Applied Genetic Technologies' key competitors?

What other stocks do shareholders of Applied Genetic Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Genetic Technologies investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Micron Technology (MU), VBI Vaccines (VBIV), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Anavex Life Sciences (AVXL), Galmed Pharmaceuticals (GLMD) and Genocea Biosciences (GNCA).

Who are Applied Genetic Technologies' key executives?

Applied Genetic Technologies' management team includes the following people:
  • Ms. Susan B. Washer, Pres, CEO & Director (Age 59, Pay $777.27k)
  • Dr. Mark S. Shearman, Chief Scientific Officer (Age 60, Pay $538.93k)
  • Dr. Matthew Feinsod, Exec. VP of Global Strategy & Devel. (Age 49, Pay $711.2k)
  • Dr. Nicholas Muzyczka, Co-Founder
  • Dr. Barry J. Byrne, Co-Founder

What is Applied Genetic Technologies' stock symbol?

Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."

Who are Applied Genetic Technologies' major shareholders?

Applied Genetic Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.72%). Company insiders that own Applied Genetic Technologies stock include Patrick Johan Hendrik Krol, Susan B Washer, William A Sullivan and William Aliski.
View institutional ownership trends for Applied Genetic Technologies

Which major investors are buying Applied Genetic Technologies stock?

AGTC stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. Company insiders that have bought Applied Genetic Technologies stock in the last two years include Patrick Johan Hendrik Krol, Susan B Washer, William A Sullivan, and William Aliski.
View insider buying and selling activity for Applied Genetic Technologies

How do I buy shares of Applied Genetic Technologies?

Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Applied Genetic Technologies' stock price today?

One share of AGTC stock can currently be purchased for approximately $5.46.

How big of a company is Applied Genetic Technologies?

Applied Genetic Technologies has a market capitalization of $141.20 million and generates $2.45 million in revenue each year. The biotechnology company earns $-45,890,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis. Applied Genetic Technologies employs 85 workers across the globe.

What is Applied Genetic Technologies' official website?

The official website for Applied Genetic Technologies is www.agtc.com.

How can I contact Applied Genetic Technologies?

Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at 386-462-2204.

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.